sacituzumab
gilead
['sacituzumab', 'mbc', 'bcsm']
 presents updated survival data for sacituzumab in hr+/her2- #mbc: 3.3 mo os benefit (21% in risk of death) regardless of trop-2 expression and in both her2 0 and low populations. #asco23 #bcsm 
Breast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast 🎤 Co-lead @cosmocollab. Focus on survivorship and social media in oncology.